^
DRUG:

Herceptin (trastuzumab)

i
Other names: RG597, R 597, R597
Company:
Roche
Drug class:
HER2 inhibitor
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive + CAV1 overexpression
Gastric Cancer
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
Gastric Cancer
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Hormone Receptor Negative Breast Cancer
HER-2 overexpression
Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Breast Cancer
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastric Cancer
HER-2 amplification
CRC
ER positive
HER2 Positive Breast Cancer
HER-2 expression
Endometrial Adenocarcinoma
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
GastroEsophageal Cancer
HER-2 positive
Esophageal Adenocarcinoma
HER-2 overexpression
Esophageal Adenocarcinoma
HR positive
HER2 Positive Breast Cancer
HER-2 positive
Salivary Gland Cancer
HER-2 positive
Endometrial Cancer
HER-2 mutation
NSCLC
HER-2 overexpression
Gastric Adenocarcinoma
HER-2 amplification
CRC
HR positive
HER2 Positive Breast Cancer
HER-2 amplification
Rectal Cancer
HER-2 amplification
Rectal Cancer
PIK3CA E545
HER2 Positive Breast Cancer
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
PIK3CA G1049R
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
HER-2 amplification
Gastric Cancer
HER-2 amplification
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
HER-2 expression
Cholangiocarcinoma
ER positive
HER2 Positive Breast Cancer
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastric Cancer
ADRB2 overexpression
HER2 Positive Breast Cancer
PD-L1-H
HER2 Positive Breast Cancer
PD-1 overexpression
HER2 Positive Breast Cancer
MYBL2 overexpression
HER2 Positive Breast Cancer
PIK3CA mutation
HER2 Positive Breast Cancer
PIK3CA E542K
HER2 Positive Breast Cancer
PIK3CA M1043I
HER2 Positive Breast Cancer
PIK3CA H1047
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
PIK3CA Q546
HER2 Positive Breast Cancer
HR positive + HER-2 positive
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Gallbladder Cancer
HER-2 positive
Small Cell Lung Cancer
HER-2 overexpression
Endometrial Adenocarcinoma
HER-2 positive
Endometrial Adenocarcinoma
HER-2 overexpression
Endometrial Cancer
HER-2 positive
NSCLC
HER-2 overexpression
Esophageal Cancer
HER-2 positive
GastroEsophageal Cancer
HER-2 overexpression
Pancreatic Cancer
HER-2 overexpression
Salivary Gland Cancer
HER-2 overexpression
Cervical Cancer
HER-2 positive
Esophageal Adenocarcinoma
HER-2 overexpression
Urothelial Cancer
HER-2 positive
Esophageal Squamous Cell Carcinoma
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
HER-2 amplification
Gastric Cancer
HER-2 overexpression
Salivary Gland Cancer
HER-2 amplification
Cholangiocarcinoma
HER-2 expression
HER2 Positive Breast Cancer
HER-2 expression
Gastric Cancer
PIK3CA mutation
HER2 Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
HER-2 amplification
Breast Cancer
HR positive + HER-2 amplification
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
HER-2 mutation
Hormone Receptor Positive Breast Cancer
HR positive + HER-2 mutation
HER2 Positive Breast Cancer
ER negative
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
Breast Cancer
ER positive
Breast Cancer
ER negative
Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 mutation
NSCLC
ER positive + PGR positive
HER2 Positive Breast Cancer
PD-L1 expression
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
ER positive
HER2 Positive Breast Cancer
ER positive
HER2 Negative Breast Cancer
HER-2 amplification
Esophageal Adenocarcinoma
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our